Dr.Reddy's Announces Five ANDA Approvals, Generic Product Launches In US

Dr.Reddy's Laboratories announced that it launched five products in US market during the month of January 2009. The company launched Levetiracetam tablets of 250 mg, 500 mg, 750 mg, & 1000 mg, the generic version of UCB Keppra tablets with annual sales of $1.1 billion. The company also launched Omeprazole capsules of 40 mg with generic version of AstraZeneca's Prilosec with annual sales of $168 million.

The company launched Lamotragine CD chewable tablets of 5 mg and 25 mg, the generic version of GlaxoSmithKline's Lamictal CD tablets with annual sales of $87 million, Divalproex capsules & delayed release pellets of 125 mg, the generic version of Abbott's Depakote delayed release capsules of 125 mg with IMS annual sales of $126 million. The company also launched Lamotrigine tablets of 25 mg, 100 mg, 150 mg and 200 mg, the generic version of GlaxoSmithKline's Lamictal tablets with annual sales of $2.3 billion as per IMS data.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com